Arrowstreet Capital’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Arrowstreet Capital’s Portfolio SGNT Stock Details SGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-86,298	Closed	-$2.23M	–	1231
2014 Q2	$2.23M	Buy	86,298 +8,372	+11%	+$186K	0.01%	567
2014 Q1	$1.82M	Buy	77,926 +19,733	+34%	+$432K	0.01%	677
2013 Q4	$1.48M	Buy	58,193 +4,113	+8%	+$92.9K	0.01%	741
2013 Q3	$1.1M	Buy	+54,080	New	+$1.2M	0.01%	648

Other funds holding SGNT

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Arrowstreet Capital's SGNT Position: Q3 2014 in Review

Arrowstreet Capital sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2014, closing a stake of 86,298 shares — an estimated $2.23M sold.

Arrowstreet Capital first reported a position in SGNT in Q3 2013 and held it in 4 quarters. The position peaked at $2.23M in Q2 2014. 114 funds tracked by Wall St. Rank hold SGNT as of Q3 2014.

Arrowstreet Capital reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2014 after selling out during the quarter.
Arrowstreet Capital sold 86,298 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2014, an estimated $2.23M.
Arrowstreet Capital first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2013 and held it in 4 quarters.
Arrowstreet Capital's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $2.23M in Q2 2014.
114 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2014.

Based on Arrowstreet Capital's 13F filing for Q3 2014, filed 14 Nov 2014.